ASCO: Roche’s Columvi combination shows survival advantage

Swiss pharma major Roche (ROG: SIX) has reported updated results from its Phase III STARGLO trial, showing that a fixed-duration regimen of Columvi (glofitamab) combined with gemcitabine and oxaliplatin (GemOx) continues to deliver a notable survival benefit for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The findings, set to be presented at the American Society of Clinical Oncology annual meeting, bolster previous results indicating that this bispecific antibody regimen may offer a longer-lasting, readily available treatment alternative for patients who have undergone at least one prior therapy and are ineligible for autologous stem cell transplant.

As an “off-the-shelf” treatment with a fixed-duration approach, Columvo could potentially ease access and improve patient convenience.